Emyria’s CALM-GUT study of irritable bowel syndrome (IBS) has received strong interest from patients, with up to 200 expected to take part over 12 months.
The observational study aims to provide evidence of the efficacy and safety of routinely prescribed medicinal cannabis for the management of symptoms in patients with IBS.
It will complement Emyria’s recent mental health-focussed drug development program and inform development of the company’s second cannabinoid-based drug candidate.
Emyria managing director Dr Michael Winlo said: “IBS can be a challenging condition to manage and the strong interest demonstrates the need for safe and effective options.
“We were encouraged to initiate this study based on an analysis of our Real-World Evidence and have designed it to support our second drug development program EMD-004.”
For more details, click here.
